TUMOR MARKERS EXPRESSION LEVELS IN GASTRIC CANCER PATIENT'S PERIPHERAL BLOOD BY RT-PCR ASSESSMENT

Imagem de Miniatura
Arquivos
art_KAWAKAMI_TUMOR_MARKERS_EXPRESSION_LEVELS_IN_GASTRIC_CANCER_PATIENTS_2023.PDF (1.3 MB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
COLEGIO BRASILEIRO CIRURGIA DIGESTIVA-CBCD
Autores
Citação
ABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA-BRAZILIAN ARCHIVES OF DIGESTIVE SURGERY, v.36, article ID e1789, 8p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUND: Hematological recurrence is the second most frequent cause of failure in the treatment of gastric cancer. The detection of circulating tumor markers in peripheral blood by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) method may be a useful tool to predict recurrence and determine the patient's prognosis. However, no consensus has been reached regarding the association between the tumor markers level in peripheral blood and its impact on patient survival. AIMS: To evaluate the expression of the circulating tumor markers CK20 and MUC1 in peripheral blood samples from patients with gastric cancer by qRT-PCR, and to verify the association of their expression levels with clinicopathological characteristics and survival. METHODS: A total of 31 patients with gastric adenocarcinoma were prospectively included in this study. CK20 and MUC1 expression levels were analyzed from peripheral blood by the qRT-PCR technique. RESULTS: There was no statistically significant (p>0.05) association between CK20 expression levels and clinical, pathological, and surgical features. Higher MUC1 expression levels were associated with female patients (p=0.01). There was a correlation between both gene levels (R=0.81, p<0.001), and CK20 level and tumor size (R=0.39, p=0.034). CONCLUSIONS: CK20 and MUC1 expression levels could be assessed by qRT-PCR from total peripheral blood samples of patients with gastric cancer. CK20 levels were correlated to MUC1 levels as well as to tumor size. There was no difference in disease-free survival and overall survival regarding both genetic markers expression in this series
Palavras-chave
Stomach Neoplasms, Gastrectomy, Tumor Biomarkers, Neoplasm Metastasis Reverse Transcriptase Polymerase Chain Reaction
URI
https://observatorio.fm.usp.br/handle/OPI/58873
Referências
  1. Abib, 1997, Cad Saude Publica, V13 Suppl 1, P99
  2. Arigami T, 2013, ANN SURG ONCOL, V20, P515, DOI 10.1245/s10434-012-2355-x
  3. Baldus SE, 1998, INT J CANCER, V79, P133, DOI 10.1002/(SICI)1097-0215(19980417)79:2<133::AID-IJC6>3.0.CO;2-U
  4. Barchi LC, 2021, ABCD-ARQ BRAS CIR DI, V34, DOI 10.1590/0102-672020210001e1563
  5. Dardaei L, 2011, CLIN BIOCHEM, V44, P325, DOI 10.1016/j.clinbiochem.2010.11.005
  6. de Assumpçao PP, 2023, ABCD-ARQ BRAS CIR DI, V36, DOI 10.1590/0102-672020230034e1752
  7. Ghossein RA, 2000, EUR J CANCER, V36, P1681, DOI 10.1016/S0959-8049(00)00152-0
  8. Huang XZ, 2015, INT J CANCER, V136, P21, DOI 10.1002/ijc.28954
  9. Ikeguchi M, 2003, INT J MOL MED, V11, P217
  10. Illert B, 2005, SCAND J GASTROENTERO, V40, P843, DOI 10.1080/00365520510015557
  11. Ito S, 2002, CANCER LETT, V183, P195, DOI 10.1016/S0304-3835(02)00157-X
  12. Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107, 10.3322/caac.21492]
  13. Ramos MFKP, 2022, ABCD-ARQ BRAS CIR DI, V35, DOI 10.1590/0102-672020210002e1648
  14. Kubisch I, 2015, ONCOLOGY-BASEL, V89, P294, DOI 10.1159/000437373
  15. Kubota K, 2003, INT J CANCER, V105, P136, DOI 10.1002/ijc.11031
  16. Lee E, 2002, CANCER, V94, P2867, DOI 10.1002/cncr.10562
  17. Maehara Y, 1996, SURGERY, V119, P397, DOI 10.1016/S0039-6060(96)80138-3
  18. Majima T, 2000, JPN J CLIN ONCOL, V30, P499, DOI 10.1093/jjco/hyd130
  19. Mori M, 1998, J CLIN ONCOL, V16, P128, DOI 10.1200/JCO.1998.16.1.128
  20. Natsugoe S, 2013, INT J CLIN ONCOL, V18, P752, DOI 10.1007/s10147-013-0577-y
  21. Ohlsson L, 2006, BRIT J CANCER, V95, P218, DOI 10.1038/sj.bjc.6603206
  22. Okada Y, 2001, CANCER-AM CANCER SOC, V92, P2056, DOI 10.1002/1097-0142(20011015)92:8<2056::AID-CNCR1545>3.0.CO;2-L
  23. Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113
  24. Pereira MA, 2017, ABCD-ARQ BRAS CIR DI, V30, P30, DOI 10.1590/0102-6720201700010009
  25. Pinto-de-Sousa J, 2002, VIRCHOWS ARCH, V440, P304, DOI 10.1007/s00428-001-0548-y
  26. Rawla P, 2019, GASTROENTEROL REV, V14, P26, DOI 10.5114/pg.2018.80001
  27. Reis CA, 1998, INT J CANCER, V79, P402, DOI 10.1002/(SICI)1097-0215(19980821)79:4<402::AID-IJC16>3.0.CO;2-6
  28. Saeki N, 2014, INT J MOL SCI, V15, P7958, DOI 10.3390/ijms15057958
  29. Shin JH, 2002, ALIMENT PHARM THERAP, V16, P137, DOI 10.1046/j.1365-2036.16.s2.33.x
  30. SMITH B, 1991, LANCET, V338, P1227, DOI 10.1016/0140-6736(91)92100-G
  31. Soeth E, 1997, CANCER RES, V57, P3106
  32. Sonoda H, 2006, ONCOL REP, V16, P411
  33. Takami H, 2012, PATHOBIOLOGY, V79, P154, DOI 10.1159/000335694
  34. Tani N, 2007, ANTICANCER RES, V27, P1207
  35. Uen YH, 2006, CLIN CHIM ACTA, V367, P55, DOI 10.1016/j.cca.2005.11.013
  36. Uenosono Y, 2013, CANCER-AM CANCER SOC, V119, P3984, DOI 10.1002/cncr.28309
  37. Wu ZY, 2007, WORLD J GASTROENTERO, V13, P4122, DOI 10.3748/wjg.v13.i30.4122
  38. Yamamoto N, 1997, CANCER, V80, P1393, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1393::AID-CNCR5>3.0.CO;2-G

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT